A Study to Evaluate the Effect of IMB-1018972 on Cardiac Energetics in Patients With Type 2 Diabetes (IMPROVE-DiCE)

• Status: Recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imbria Pharmaceuticals, Inc.
• Collaborator: University of Oxford

Criteria

Inclusion Criteria:

• Diagnosis of type 2 diabetes

• Elevated HbA1c

• Elevated BMI

• Preserved left ventricular ejection fraction

Exclusion Criteria:

• Uncontrolled hypertension

• Contraindication to magnetic resonance scanning

• More than mild to moderate valvular heart disease

• Atrial fibrillation

• History of sustained ventricular tachycardia or cardiac arrest

• Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability